EXCLUSIVE: Merck Serono set to end product drought as early as end-2016 with two cancer drugs in late stage trials

17 August 2015

If all goes according to plan, Merck Serono - the pharma business unit of Germany's Merck KGaA (MRK: DE) - may be looking at two new drug launches in the cancer segment as early as end-2016, the company’s R&D chief Luciano Rossetti said in an exclusive interview with The Pharma Letter.

Dr Rossetti is quick to acknowledge the fact that the pharma major hasn’t had a breakthrough drug in a decade but emphasises that given the research pipeline, things are looking up. “The company has two drugs in the cancer segment in late stage trials and we are focussed at building an aggressive pipeline of trial drugs,” he says.

The company expects definitive results from the trials of evofosfamide and avelumab, soon, with a launch estimated by the end of 2016-17.

Product Pipeline

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK